From:
(SANTE)
Sent:
mercredi 17 juin 2020 13:06
To:
(SANTE);
(SANTE);
(SANTE);
(SANTE);
(SANTE);
(SANTE)
Cc:
(SANTE)
Subject:
BTO : DG EMPL Working Group with social partners on pharma and
chemicals strategy
Attachments:
Working Group Agenda_17.06.2020_v4.docx
17 June 2020
Meeting with DG EMPL and European Chemical Employers Group and industriAll European Trade
Union International Trade Union House held through Kudo.
Point 4. Chemical Strategy for Sustainability and Pharmaceutical Strategy for Europe
DG EMPL (contact
) asked us to provide a presentation on the elements of the
pharmaceutical strategy.
There was a lot on interest from interlocutors who generally welcomed the objectives of the strategy.
Questions from interlocutors included the following topics:
-
How is the Commission planning to tackle shortages in terms of actions?
-
What actions will promote innovation for unmet needs?
-
Would the Commission involve social partners in the consultation process (like trade unions,
-
Innovation for small start ups needs to be a priority.
-
How does the Commission see the intention by DE, NL to repatriate API production?
-
system of intellectual property or other incentives?
In my replies I mentioned the ongo
specifically mention the alliance on APIs but mentioned that the Commission is engaging in cooperation
with other DGs with Pharmaceutical industry and other partners in the API value chain to develop
solutions.
At this point we cannot mention the specific actions on promoting innovation for unmet needs, but
there is a thought process internally which is based on data from existing studies and evaluation of O/P
which can inform policy options.
On the consultation process social partners are definitely concerned and we encourage them to
participate in the consultation actions which are now open.
Regarding innovation and encouraging SMEs we agree that actions go beyond pharma. This is why the
strategy follows a holistic approach which includes, funding & capital venture, better connection of
academic knowledge and industry, knowledge upscaling, regulatory simplification and final y evaluation
of the existing incentives.
END